Leidos wins $318M contract for MHS GENESIS transition support
Leidos (LDOS) has been awarded a $318M contract by the Defense Health Agency to support the MHS GENESIS electronic health record system. The contract, lasting until January 2028, covers system reintegration, software licensing, and hosting services.
How this was made
The 30-second read
Why it matters
The $318M award extends Leidos' role in MHS GENESIS, likely improving its revenue visibility for FY2027.
Market read
A sizable new federal contract for a mid‑cap defense contractor, offering a clear catalyst for short‑term price movement.
What to watch
Potential cost overruns or integration challenges could affect profitability.
Background
Leidos (LDOS) is a leading U.S. defense and IT services firm; the Defense Health Agency manages military health records.
Ticker impact
Leidos secured a $317.99M contract from the Defense Health Agency for MHS GENESIS transition support.
upward pressure as investors price in the new revenue stream
Large, firm‑fixed‑price award to a mid‑cap defense contractor is material and likely to boost earnings outlook.
Market effects
May lift other defense and government‑contractors as the award signals continued federal spending.
U.S. defense sector could see modest gains.
Limited to U.S. defense equities.
Counterpoint
If the contract faces execution delays, the upside could be muted.
Key entities
- companyLeidos
U.S. defense contractor and IT services provider.
- government agencyDefense Health Agency
U.S. Department of Defense agency overseeing military health records.


